Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Catalyst Pharmaceuticals (CPRX) Share Price

Press coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.6063591860623 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

CPRX has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. SunTrust Banks set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $6.25.

Catalyst Pharmaceuticals (CPRX) traded down $0.07 on Monday, hitting $4.33. 2,242,114 shares of the company traded hands, compared to its average volume of 968,937. Catalyst Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $4.51.

In related news, insider Patrick J. Mcenany purchased 20,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the transaction, the insider now directly owns 4,471,026 shares in the company, valued at $11,535,247.08. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 9.60% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Catalyst Pharmaceuticals (CPRX) Share Price” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/catalyst-pharmaceuticals-cprx-getting-somewhat-favorable-media-coverage-study-shows.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply